[
  {
    "ts": "2025-10-19T14:57:00+00:00",
    "headline": "2 High-Yield Dividend Stocks Too Cheap to Ignore",
    "summary": "They are both yielding above 5%.",
    "url": "https://www.fool.com/investing/2025/10/19/2-high-yield-dividend-stocks-too-cheap-to-ignore/",
    "source": "Motley Fool",
    "provider": "yfinance",
    "raw": {
      "id": "fcabf286-b255-3ba9-816a-e87a3c2b0bfb",
      "content": {
        "id": "fcabf286-b255-3ba9-816a-e87a3c2b0bfb",
        "contentType": "STORY",
        "title": "2 High-Yield Dividend Stocks Too Cheap to Ignore",
        "description": "",
        "summary": "They are both yielding above 5%.",
        "pubDate": "2025-10-19T14:57:00Z",
        "displayTime": "2025-10-19T14:57:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/motleyfool.com/c117fdb2659300b72c4c99cd361bd3ad",
          "originalWidth": 2121,
          "originalHeight": 1414,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/ehJQ0Wam98zjxhbEB_eRNw--~B/aD0xNDE0O3c9MjEyMTthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/motleyfool.com/c117fdb2659300b72c4c99cd361bd3ad.cf.webp",
              "width": 2121,
              "height": 1414,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Pzk1fDRxCV2EbAXZEv6auQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/motleyfool.com/c117fdb2659300b72c4c99cd361bd3ad.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Motley Fool",
          "url": "http://www.fool.com/"
        },
        "canonicalUrl": {
          "url": "https://www.fool.com/investing/2025/10/19/2-high-yield-dividend-stocks-too-cheap-to-ignore/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/2-high-yield-dividend-stocks-145700534.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            },
            {
              "symbol": "BMY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-19T08:15:00+00:00",
    "headline": "XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer",
    "summary": "NEW YORK & NORTHBROOK, Ill., October 19, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, \"Astellas\") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (BCR) a",
    "url": "https://finance.yahoo.com/news/xtandi-plus-leuprolide-reduced-risk-081500878.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "a2c9635a-a221-3109-9d56-125875f97526",
      "content": {
        "id": "a2c9635a-a221-3109-9d56-125875f97526",
        "contentType": "STORY",
        "title": "XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer",
        "description": "",
        "summary": "NEW YORK & NORTHBROOK, Ill., October 19, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, \"Astellas\") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (BCR) a",
        "pubDate": "2025-10-19T08:15:00Z",
        "displayTime": "2025-10-19T08:15:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/b012e61537a120567bbcfd030be1e12e",
          "originalWidth": 480,
          "originalHeight": 212,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/oQ8QcuvHaqr.BOb62g6L3g--~B/aD0yMTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b012e61537a120567bbcfd030be1e12e.cf.webp",
              "width": 480,
              "height": 212,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/TZS.XrmvPDbrrW8IUjxN_A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/b012e61537a120567bbcfd030be1e12e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/xtandi-plus-leuprolide-reduced-risk-081500878.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/xtandi-plus-leuprolide-reduced-risk-081500878.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-10-19T06:30:00+00:00",
    "headline": "Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer",
    "summary": "NEW YORK, October 19, 2025--Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adults with metastatic non-small cell lung cancer (mNSCLC) with a BRAF V600E mutation. In treatment-naïve patients, the median overall survival (OS) was 47.6 months (95% confidence interval [CI], 31.3, not estimable) after a median follow-up of 52.3 months. In previously treated pati",
    "url": "https://finance.yahoo.com/news/pfizer-braftovi-mektovi-shows-sustained-063000452.html",
    "source": "Business Wire",
    "provider": "yfinance",
    "raw": {
      "id": "08268825-5f68-35da-bf23-7a9798c5e609",
      "content": {
        "id": "08268825-5f68-35da-bf23-7a9798c5e609",
        "contentType": "STORY",
        "title": "Pfizer’s BRAFTOVI® + MEKTOVI® Shows Sustained Long-Term Survival in Patients with Advanced Lung Cancer",
        "description": "",
        "summary": "NEW YORK, October 19, 2025--Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adults with metastatic non-small cell lung cancer (mNSCLC) with a BRAF V600E mutation. In treatment-naïve patients, the median overall survival (OS) was 47.6 months (95% confidence interval [CI], 31.3, not estimable) after a median follow-up of 52.3 months. In previously treated pati",
        "pubDate": "2025-10-19T06:30:00Z",
        "displayTime": "2025-10-19T06:30:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/business-wire.com/71dc45bd12d27f2d242a055fe53fc979",
          "originalWidth": 480,
          "originalHeight": 212,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/5_MEUfcK6DkYF4sSFOzTVw--~B/aD0yMTI7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/71dc45bd12d27f2d242a055fe53fc979.cf.webp",
              "width": 480,
              "height": 212,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uojauyJXia.Uwc_KLoH0eg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/71dc45bd12d27f2d242a055fe53fc979.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Business Wire",
          "url": "http://www.businesswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-braftovi-mektovi-shows-sustained-063000452.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/pfizer-braftovi-mektovi-shows-sustained-063000452.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]